Biocrossroadslinx Inc is categorized under Commercial Biotechnical Research in Indianapolis, IN and active since 2007.
Biocrossroadslinx Inc was established in 2007, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Dr Chip Rutledge at the company’s single location by writing to 300 North Meridian St, Indianapolis, Indiana IN 46204 or by phoning (317) 238-2450. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Biocrossroadslinx Inc |
| Contact Person: | Dr Chip Rutledge |
| Address: | 300 North Meridian St, Indianapolis, Indiana 46204 |
| Phone Number: | (317) 238-2450 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2007 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Biocrossroadslinx Inc was started in 2007 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Dr Chip Rutledge for inquiries that concern Biocrossroadslinx Inc by calling the company number (317) 238-2450, as your correspondence is most welcome. Additionally, the physical location of the single location of Biocrossroadslinx Inc can be found at the coordinates 39.771481,-86.158082 as well as the street address 300 North Meridian St in Indianapolis, Indiana 46204.
For its online presence, you may visit Biocrossroadslinx Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.